Breast Cancer Associated Antibodies - Full Text View

Sponsored by:	Lab Discoveries Ltd.
Information provided by:	Lab Discoveries Ltd.
ClinicalTrials.gov Identifier:	NCT00331942

Purpose

To determine the ability of the Cimmunology process to lead to in vitro antibody production, the ability of the ELISA assays to detect any of those antibodies, and to establish the relationship between the ELISA results and the clinical / pathological status of the patient. The statistical significance of the CAAb test results will be determined.

Condition
Breast Cancer

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

Drug Information available for: Immunoglobulins Globulin, Immune

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening, Cross-Sectional, Defined Population, Retrospective/Prospective Study
Official Title:	Study of Breast Cancer Associated Antibodies

Further study details as provided by Lab Discoveries Ltd.:

Estimated Enrollment:	100
Study Start Date:	July 2006
Estimated Study Completion Date:	May 2008

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria BC:

Subjects 18 years or over.
Patients diagnosed with suspected breast cancer, (positive mammography or ultrasound or physical examination) and have a positive biopsy.
Patients willing to participate as evidenced by signing the written informed consent.

Exclusion Criteria BC:

Subjects less than 18 years
Patients with prior history of other tumors (except skin cancer)
Hematologic systemic disorders
Patients that have undergone chemotherapy
Patients that have been under anesthesia in the last three months.
Patient not willing to sign written informed consent.

Inclusion Criteria Control -

Subjects 18 years or over
Patients willing to participate as evidenced by signing the written informed consent
Subjects had a negative mammography in the past three months.

Exclusion Criteria Control -

Subjects less than 18 years
Hematological malignancies
History of any past tumors
Other breast pathology
Patients that have been under anesthesia in the last three months
Patients treated with immuno-suppressant drugs
Patient not willing to sign written informed consent

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00331942

Contacts

Contact: Alon Hayka

+972 544 631237

alonhayka@yahoo.com

Locations

Israel
Soroka	Recruiting
Beer-Sheva, Israel
Contact: Michal Koretz, Dr. 972 8 6403336
Carmel Medical center	Recruiting
Haifa, Israel
Contact: Pnina Engelman, Dr. 972 4 8787909

Sponsors and Collaborators

Lab Discoveries Ltd.

Investigators

Principal Investigator:

Tamar J Cohen, Phd.

Lab Discoveries

More Information

Study ID Numbers:	LD-BC-CAAb
Study First Received:	May 27, 2006
Last Updated:	March 1, 2007
ClinicalTrials.gov Identifier:	NCT00331942
Health Authority:	Israel: Ministry of Health

Keywords provided by Lab Discoveries Ltd.:

Breast
Cancer
Associated
Antibodies

Study placed in the following topic categories:

Antibodies
Skin Diseases
Breast Neoplasms
Breast Diseases
Immunoglobulins

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009